Glomerular injury and renal disease manifestations are reduced in MRL/lpr Mif−/− mice (12), and pharmacologic MIF antagonists protect against glomerulonephritis in lupus-prone MRL/lpr or NZB/NZW F1 mice (13). Here, MIF is linked to systemic lupus erythematosus.